Synopsis Clinical evidence suggests that tafamidis slow the progression of peripheral neurologic impairment in transthyretin amyloid polyneuropathy. The present study aims to determine the efficacy and safety of tafamidis in patients with hereditary and wildtype transthyretin amyloid cardiomyopathy. This week’s “ MED FACT ” discusses a clinical study from The New England Journal of Medicine, “ Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy ”. Aug 2018. Authors : Mathew S.
Maurer; Jeffrey H. Schwartz; Balarama Gundapaneni; et.al. Key Takeaways: Tafamidis treatment reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy. Objective: To determine the efficacy and safety of tafamidis in patients with transthyretin amyloid cardiomyopathy Study Type: Phase 3, multicenter, international,…
